About Stuart Therapeutics

Stuart Therapeutics is a biotechnology company that offers PolyCol, a therapeutic platform for ophthalmic indications. PolyCol’s unique method of action results in accelerated healing and recovery in various ophthalmic disease states and offers a new way to address indications such as dry eye disease, dry age related macular degeneration, and glaucoma. PolyCol is based on patented research from a major U.S. university, combined with additional intellectual property acquired by Stuart Therapeut

Company Highlights
Year Founded

2017

icon-altEmployees

7

Location (HQ)

USA

Since Last Funding

3 years 5 months

Monthly Website Visitors

1.5K

icon-altTotal Investment Amt

$11M

Last Funding Round

Series A

icon-altYoY Headcount Growth

16.39%

Key Metrics

Senior Hires

NameLinkedin ProfilePositionDate Joined
John Doehttps://www.linkedin.com/in/johndoeCEOCEO
Jane Doehttps://www.linkedin.com/in/janedoeCTOCTO
John Smithhttps://www.linkedin.com/in/johnsmithCFOCFO
Jane Smithhttps://www.linkedin.com/in/janesmithCOOCOO
Get API access to complete private company database with growth metrics from 15 sources

Similar Companies

Health Care

Biotechnology

Therapeutics